Aurinia Pharmaceuticals Statistics
Share Statistics
Aurinia Pharmaceuticals has 143.18M shares outstanding. The number of shares has increased by -0.3% in one year.
| Shares Outstanding | 143.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 128.68M |
| Failed to Deliver (FTD) Shares | 339 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 7.34M, so 5.13% of the outstanding shares have been sold short.
| Short Interest | 7.34M |
| Short % of Shares Out | 5.13% |
| Short % of Float | 5.71% |
| Short Ratio (days to cover) | 8.86 |
Valuation Ratios
The PE ratio is -16.5 and the forward PE ratio is 15.52.
| PE Ratio | -16.5 |
| Forward PE | 15.52 |
| PS Ratio | 7.34 |
| Forward PS | 4.8 |
| PB Ratio | 3.41 |
| P/FCF Ratio | -37.67 |
| PEG Ratio | n/a |
Enterprise Valuation
Aurinia Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.34B.
| EV / Earnings | -17.13 |
| EV / Sales | 7.61 |
| EV / EBITDA | -21.2 |
| EV / EBIT | -14.58 |
| EV / FCF | -39.1 |
Financial Position
The company has a current ratio of 5.5, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.5 |
| Quick Ratio | 4.99 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 3.96 |
| Cash Flow / Debt | -2.15 |
| Interest Coverage | -33.04 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is -19.42%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.14% |
| Return on Capital (ROIC) | -19.42% |
| Revenue Per Employee | 585.04K |
| Profits Per Employee | -260.07K |
| Employee Count | 300 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.36 |
Taxes
| Income Tax | 551.00K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -0.21% in the last 52 weeks. The beta is 1.46, so Aurinia Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.46 |
| 52-Week Price Change | -0.21% |
| 50-Day Moving Average | 7.95 |
| 200-Day Moving Average | 6.26 |
| Relative Strength Index (RSI) | 64.47 |
| Average Volume (20 Days) | 1.27M |
Income Statement
In the last 12 months, Aurinia Pharmaceuticals had revenue of $175.51M and earned -$78.02M in profits. Earnings per share was $-0.54.
| Revenue | 175.51M |
| Gross Profit | 161.37M |
| Operating Income | -91.69M |
| Net Income | -78.02M |
| EBITDA | -63.05M |
| EBIT | -91.69M |
| Earnings Per Share (EPS) | -0.54 |
Balance Sheet
The company has $48.88M in cash and $97.61M in debt, giving a net cash position of -$48.73M.
| Cash & Cash Equivalents | 48.88M |
| Total Debt | 97.61M |
| Net Cash | -48.73M |
| Retained Earnings | -942.32M |
| Total Assets | 549.36M |
| Working Capital | 361.85M |
Cash Flow
In the last 12 months, operating cash flow was -$33.46M and capital expenditures -$718.00K, giving a free cash flow of -$34.18M.
| Operating Cash Flow | -33.46M |
| Capital Expenditures | -718.00K |
| Free Cash Flow | -34.18M |
| FCF Per Share | -0.24 |
Margins
Gross margin is 91.94%, with operating and profit margins of -52.24% and -44.45%.
| Gross Margin | 91.94% |
| Operating Margin | -52.24% |
| Pretax Margin | -44.14% |
| Profit Margin | -44.45% |
| EBITDA Margin | -35.92% |
| EBIT Margin | -52.24% |
| FCF Margin | -19.47% |
Dividends & Yields
AUPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.76% |
| FCF Yield | -2.55% |
Analyst Forecast
The average price target for AUPH is $10, which is 6.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 6.7% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Oct 23, 2013. It was a backward split with a ratio of 1:50.
| Last Split Date | Oct 23, 2013 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | 3.85 |
| Piotroski F-Score | 4 |